Characteristics of B-Precursor Specimens at Diagnosis
| No. . | Paired* . | Age (yr)† . | Sex . | Race . | WBC†‡ . | %Sρ . | % Blasts† . | RD (mo)1-155 . | Therapy . | DHFR1-154 . | %1-154 . | Cytogenetics . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BP1 | 5.5 | M | AA | 35,000 | 8.7 | 100 | On Rx | −1-167 | 2.6 | 100 | 46,XY/46,XY,del(4),del(6) | |
| BP2 | 6 | F | W | 18,600 | 1.3 | 99 | On Rx | −1-167 | 2.2 | 100 | 46,XX/46,XX,t(3; 9) | |
| BP3 | 6 | M | W | 9,700 | NA | 88 | On Rx | −1-167 | 1.1 | 100 | 46,XY/47,XY,+21,−13,der(9)t(9;?), | |
| der(12)t(12;?) | ||||||||||||
| BP41-160 | 0.2 | M | W | 684,000 | NA | 87 | 6 | VcMtMpVmArCy | 3.6 | 100 | 46,XX | |
| BP51-160 | 4 | M | AA | 36,000 | 2.5 | 92 | 15 | PrVcAsMpCy | 2.8 | 100 | 47,XY,+21 | |
| BP61-160 | 3.5 | F | W | 16,500 | NA | 96 | Off Rx | PrVcAsMtMpAr | 1.9 | 100 | 46,XX | |
| BP71-160 | 0.67 | F | AA | 17,900 | 14.4 | 95 | 5 | MtVmArCy | 3.3/18.0 | 32/68 | 46,XX/46,XX,t(11; 19) | |
| BP81-160 | 4 | F | W | 5,400 | NA | 88 | Off Rx | PrVcAsMtMpAr | 2.4 | 100 | NA | |
| BP91-160 | rBP6 | 4 | F | W | 23,000 | 1.8 | 98 | 24 | PrVcAsMtMpAr | 1.8 | 100 | 46,XX/46,XX,der(13),t(1; 13) |
| BP101-160 | 3.5 | F | W | 9,800 | 4.3 | 94 | Off Rx | PrVcAsMtMpAr | 1.8/17.6 | 83/17 | 46,XX/46,XX,del(12) | |
| BP111-160 | 7.5 | M | W | 31,500 | 7.1 | 95 | 351-164 | PrVcAsMtMp | 2.1 | 100 | 46,XY/54,XY,+X,+4,+8,+10,+18, | |
| +21,+21,i(7q),i(9q),+mar | ||||||||||||
| BP121-160 | 3.5 | F | AA | 38,000 | 21.8 | 96 | 9 | PrVcAsMtMpAr | 2.5/24.6 | 78/22 | 46,XX/46,XX,t(1; 19) | |
| BP131-160 | 8 | M | AA | 4,000 | 4.7 | 99 | Off Rx | PrVcAsMtMpAr | 1.9 | 100 | 46,XY/53,XY,+X,+6,+14,+17, | |
| +18,+21,+21 | ||||||||||||
| BP141-160 | 4 | M | W | 26,500 | 15.1 | 98 | 29 | PrVcAsMtMp | 2.8/20 | 69/31 | 46,XY/45,XY,−3,−7,−12,+dic | |
| (7; 12),+der(3),t(3;?) | ||||||||||||
| BP151-160 | 6.5 | F | W | 107,000 | 16.9 | 85 | 15 | PrVcAsMtMpAr | 1.6 | 100 | 46,XX/45,XX,−12,−17,−19,del(9), | |
| +der(19),t(1; 19),+dic(12; 17) | ||||||||||||
| BP16 | 7 | M | W | 5,100 | 9.9 | 97 | On Rx | −1-167 | 1.5 | 100 | 46,XY/46,XY,i(21) | |
| BP17 | 13.5 | M | AA | 72,000 | 3.5 | 93 | 36 | PrVcAsMtMpAr | 1.7 | 100 | 46,XY/46,XY,−12,−22,+dic(12; 22) | |
| BP18 | 5 | F | AA | 5,800 | 8 | 96 | Off Rx | PrVcAsMtMpAr | 2.0/19.6 | 83/17 | 46,XX | |
| BP19 | 8 | F | AA | 38,400 | 12 | 90 | 13 | PrVcAsAdMtMpAr | 4.0 | 100 | 46,XX/46,XX,t(9; 22) | |
| BP20 | rBP1 | 8 | M | AA | 17,900 | 14 | 89 | 8 | PrVcAsAdMtMpVmAr | 2.4/12.4 | 69/31 | NA |
| BP21 | 14 | F | W | 530,000 | 6.4 | 92 | 9 | PrVcAdMtMpAr | 2.4 | 100 | 46,XX/47,XXX,t(9; 22) | |
| BP22 | 5 | F | AA | 212,000 | NA | 93 | 18 | PrVcAsMtMpAr | 2.5/25.8 | 81/19 | 46,XX/46,XX,12p+,rearr17p | |
| BP23 | 2 | F | W | 12,400 | 8.6 | 89 | On Rx | −1-167 | 2.7 | 100 | NA | |
| BP24 | 12 | M | AA | 2,400 | 13.6 | 90 | On Rx | −1-167 | 2.0 | 100 | 46,XY/26,X,+16,+18,+21/52,−Y, | |
| +X,+10,+10,+18,+18, | ||||||||||||
| +21,+21 | ||||||||||||
| BP25 | 6 | F | AA | 21,000 | NA | 88 | On Rx | −1-167 | 5.5/38.7 | 85/15 | 46,XX | |
| BP26 | 5.5 | M | AA | 35,000 | 8.7 | 93 | 9 | PrVcAsDnMtMpAr | 2.7/18.8 | 89/11 | 46,XY/46,XY,der(19),t(1; 19) | |
| BP27 | 11 | M | AA | 98,500 | 2 | 92 | On Rx | −1-167 | 1.7 | 100 | NA | |
| BP28 | 11.5 | F | W | 120,000 | NA | 86 | −1-161 | −1-161 | 3.0 | 100 | 47,XX,+21 | |
| BP29 | 8 | M | W | 47,900 | 8.9 | 94 | −1-161 | −1-161 | 1.8/13.8 | 83/17 | 47,XY,+21/49,XXY,+14,+21 | |
| BP30 | 6 | F | AA | 5,700 | 4.6 | 82 | Off Rx | PrVcAsMtMp | 1.7 | 100 | NA | |
| BP31 | 4 | M | W | 3,300 | NA | 97 | Off Rx | PrVcAsMtMpAr | 1.6 | 100 | 46,XY | |
| BP32 | 9 | M | AA | 91,000 | 2.7 | 95 | On Rx | −1-167 | 1.7 | 100 | 46,XY | |
| BP331-160 | 15 | M | W | 595,000 | 4.8 | 96 | IF | PrVcAsAd | 2.1 | 100 | 46,XY/45,XY,−Y | |
| BP341-160 | 15 | M | W | 89,800 | NA | 80 | 4 | PrVcAsMtMpAr | 1.9 | 100 | NA | |
| BP351-160 | 4.5 | F | W | 216,000 | 16.1 | 99 | 14 | PrVcAsMtMpAr | 1.3 | 100 | 46,XX | |
| BP36 | 2.5 | F | W | 172,500 | 5 | 97 | On Rx | −1-167 | 1.9/9.5 | 88/12 | 46,XX/47,XX,del(9),+21 |
| No. . | Paired* . | Age (yr)† . | Sex . | Race . | WBC†‡ . | %Sρ . | % Blasts† . | RD (mo)1-155 . | Therapy . | DHFR1-154 . | %1-154 . | Cytogenetics . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BP1 | 5.5 | M | AA | 35,000 | 8.7 | 100 | On Rx | −1-167 | 2.6 | 100 | 46,XY/46,XY,del(4),del(6) | |
| BP2 | 6 | F | W | 18,600 | 1.3 | 99 | On Rx | −1-167 | 2.2 | 100 | 46,XX/46,XX,t(3; 9) | |
| BP3 | 6 | M | W | 9,700 | NA | 88 | On Rx | −1-167 | 1.1 | 100 | 46,XY/47,XY,+21,−13,der(9)t(9;?), | |
| der(12)t(12;?) | ||||||||||||
| BP41-160 | 0.2 | M | W | 684,000 | NA | 87 | 6 | VcMtMpVmArCy | 3.6 | 100 | 46,XX | |
| BP51-160 | 4 | M | AA | 36,000 | 2.5 | 92 | 15 | PrVcAsMpCy | 2.8 | 100 | 47,XY,+21 | |
| BP61-160 | 3.5 | F | W | 16,500 | NA | 96 | Off Rx | PrVcAsMtMpAr | 1.9 | 100 | 46,XX | |
| BP71-160 | 0.67 | F | AA | 17,900 | 14.4 | 95 | 5 | MtVmArCy | 3.3/18.0 | 32/68 | 46,XX/46,XX,t(11; 19) | |
| BP81-160 | 4 | F | W | 5,400 | NA | 88 | Off Rx | PrVcAsMtMpAr | 2.4 | 100 | NA | |
| BP91-160 | rBP6 | 4 | F | W | 23,000 | 1.8 | 98 | 24 | PrVcAsMtMpAr | 1.8 | 100 | 46,XX/46,XX,der(13),t(1; 13) |
| BP101-160 | 3.5 | F | W | 9,800 | 4.3 | 94 | Off Rx | PrVcAsMtMpAr | 1.8/17.6 | 83/17 | 46,XX/46,XX,del(12) | |
| BP111-160 | 7.5 | M | W | 31,500 | 7.1 | 95 | 351-164 | PrVcAsMtMp | 2.1 | 100 | 46,XY/54,XY,+X,+4,+8,+10,+18, | |
| +21,+21,i(7q),i(9q),+mar | ||||||||||||
| BP121-160 | 3.5 | F | AA | 38,000 | 21.8 | 96 | 9 | PrVcAsMtMpAr | 2.5/24.6 | 78/22 | 46,XX/46,XX,t(1; 19) | |
| BP131-160 | 8 | M | AA | 4,000 | 4.7 | 99 | Off Rx | PrVcAsMtMpAr | 1.9 | 100 | 46,XY/53,XY,+X,+6,+14,+17, | |
| +18,+21,+21 | ||||||||||||
| BP141-160 | 4 | M | W | 26,500 | 15.1 | 98 | 29 | PrVcAsMtMp | 2.8/20 | 69/31 | 46,XY/45,XY,−3,−7,−12,+dic | |
| (7; 12),+der(3),t(3;?) | ||||||||||||
| BP151-160 | 6.5 | F | W | 107,000 | 16.9 | 85 | 15 | PrVcAsMtMpAr | 1.6 | 100 | 46,XX/45,XX,−12,−17,−19,del(9), | |
| +der(19),t(1; 19),+dic(12; 17) | ||||||||||||
| BP16 | 7 | M | W | 5,100 | 9.9 | 97 | On Rx | −1-167 | 1.5 | 100 | 46,XY/46,XY,i(21) | |
| BP17 | 13.5 | M | AA | 72,000 | 3.5 | 93 | 36 | PrVcAsMtMpAr | 1.7 | 100 | 46,XY/46,XY,−12,−22,+dic(12; 22) | |
| BP18 | 5 | F | AA | 5,800 | 8 | 96 | Off Rx | PrVcAsMtMpAr | 2.0/19.6 | 83/17 | 46,XX | |
| BP19 | 8 | F | AA | 38,400 | 12 | 90 | 13 | PrVcAsAdMtMpAr | 4.0 | 100 | 46,XX/46,XX,t(9; 22) | |
| BP20 | rBP1 | 8 | M | AA | 17,900 | 14 | 89 | 8 | PrVcAsAdMtMpVmAr | 2.4/12.4 | 69/31 | NA |
| BP21 | 14 | F | W | 530,000 | 6.4 | 92 | 9 | PrVcAdMtMpAr | 2.4 | 100 | 46,XX/47,XXX,t(9; 22) | |
| BP22 | 5 | F | AA | 212,000 | NA | 93 | 18 | PrVcAsMtMpAr | 2.5/25.8 | 81/19 | 46,XX/46,XX,12p+,rearr17p | |
| BP23 | 2 | F | W | 12,400 | 8.6 | 89 | On Rx | −1-167 | 2.7 | 100 | NA | |
| BP24 | 12 | M | AA | 2,400 | 13.6 | 90 | On Rx | −1-167 | 2.0 | 100 | 46,XY/26,X,+16,+18,+21/52,−Y, | |
| +X,+10,+10,+18,+18, | ||||||||||||
| +21,+21 | ||||||||||||
| BP25 | 6 | F | AA | 21,000 | NA | 88 | On Rx | −1-167 | 5.5/38.7 | 85/15 | 46,XX | |
| BP26 | 5.5 | M | AA | 35,000 | 8.7 | 93 | 9 | PrVcAsDnMtMpAr | 2.7/18.8 | 89/11 | 46,XY/46,XY,der(19),t(1; 19) | |
| BP27 | 11 | M | AA | 98,500 | 2 | 92 | On Rx | −1-167 | 1.7 | 100 | NA | |
| BP28 | 11.5 | F | W | 120,000 | NA | 86 | −1-161 | −1-161 | 3.0 | 100 | 47,XX,+21 | |
| BP29 | 8 | M | W | 47,900 | 8.9 | 94 | −1-161 | −1-161 | 1.8/13.8 | 83/17 | 47,XY,+21/49,XXY,+14,+21 | |
| BP30 | 6 | F | AA | 5,700 | 4.6 | 82 | Off Rx | PrVcAsMtMp | 1.7 | 100 | NA | |
| BP31 | 4 | M | W | 3,300 | NA | 97 | Off Rx | PrVcAsMtMpAr | 1.6 | 100 | 46,XY | |
| BP32 | 9 | M | AA | 91,000 | 2.7 | 95 | On Rx | −1-167 | 1.7 | 100 | 46,XY | |
| BP331-160 | 15 | M | W | 595,000 | 4.8 | 96 | IF | PrVcAsAd | 2.1 | 100 | 46,XY/45,XY,−Y | |
| BP341-160 | 15 | M | W | 89,800 | NA | 80 | 4 | PrVcAsMtMpAr | 1.9 | 100 | NA | |
| BP351-160 | 4.5 | F | W | 216,000 | 16.1 | 99 | 14 | PrVcAsMtMpAr | 1.3 | 100 | 46,XX | |
| BP36 | 2.5 | F | W | 172,500 | 5 | 97 | On Rx | −1-167 | 1.9/9.5 | 88/12 | 46,XX/47,XX,del(9),+21 |
Abbreviations: W, white; AA, African-American; Ad, adriamycin; Ar, cytosine arabinoside; Cy, cyclophosphamide; Dn, daunorubicin; As, L-asparaginase; Mp, 6-mercaptopurine; Mt, methotrexate; Pr, prednisone; Vc, vincristine; Vm, Vm-26; NA, not available; IF, induction failure.
Paired relapse/diagnostic specimen. Relapse specimens are summarized in Table 3.
At diagnosis.
Units for WBCs are cells per microliter.
ρ Percentage of S-phase cells as determined by propidium iodide staining and flow cytometry.
Remission duration intervals (RD) correspond to the time from diagnosis to first relapse. Patients designated On Rx are still under treatment, whereas those designated Off Rx remain in remission and off treatment at least 30 months. In our analysis, specimens 6, 8, 10, 13, 18, 30, and 31 are from patients who are currently disease-free and off treatment.
Relative DHFR contents expressed as a single or multiple subpopulations (A/B/C). Percentage of total blasts in each subpopulation is indicated under column labeled %.
On treatment with current POG B-precursor ALL protocol including both intravenous and intramuscular Mtx.
Included in prior study.13
Testicular relapse.
Down syndrome patients not treated at parent's request.